Abstract
1. The release of bradykinin (BK) and its metabolite, des-Arg9-bradykinin (des-Arg9-BK), was studied following reperfusion of a globally ischaemic rat heart. 2. BK-like immunoreactivity increased from 13 +/- 3 (preischaemic value) to 48 +/- 12 fmol min-1 g-1 (P < 0.05, n = 14) 30 s after reperfusion. No difference in BK release was found between control hearts and hearts pretreated with the angiotensin converting enzyme (ACE or kininase II) inhibitor, enalaprilat (50 ng ml-1). 3. No significant change in des-Arg9-BK-like immunoreactivity during reperfusion was observed in control hearts. In contrast, des-Arg9-BK-like immunoreactivity rose from 44 +/- 15 to 177 +/- 61 fmol min-1 g-1 (P < 0.05, n = 7) 30 s after reperfusion in enalaprilat-treated hearts. 4. In conclusion, BK is released upon reperfusion of the globally ischaemic rat heart. ACE inhibitors, through the inhibition of kininase II, increase the formation of the active metabolite, des-Arg9-BK.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baumgarten C. R., Linz W., Kunkel G., Schölkens B. A., Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 1993 Feb;108(2):293–295. doi: 10.1111/j.1476-5381.1993.tb12797.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chahine R., Adam A., Yamaguchi N., Gaspo R., Regoli D., Nadeau R. Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol. 1993 Feb;108(2):318–322. doi: 10.1111/j.1476-5381.1993.tb12802.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Décarie A., Drapeau G., Closset J., Couture R., Adam A. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides. 1994;15(3):511–518. doi: 10.1016/0196-9781(94)90214-3. [DOI] [PubMed] [Google Scholar]
- Hartman J. C., Wall T. M., Hullinger T. G., Shebuski R. J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993 Jun;21(6):996–1003. doi: 10.1097/00005344-199306000-00022. [DOI] [PubMed] [Google Scholar]
- Linz W., Wiemer G., Schölkens B. A. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol. 1992 Aug;24(8):909–919. doi: 10.1016/0022-2828(92)91103-c. [DOI] [PubMed] [Google Scholar]
- Massoudy P., Becker B. F., Gerlach E. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol. 1994 Apr;23(4):632–639. doi: 10.1097/00005344-199404000-00017. [DOI] [PubMed] [Google Scholar]
- Nakhostine N., Ribuot C., Lamontagne D., Nadeau R., Couture R. Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol. 1993 Sep;110(1):71–76. doi: 10.1111/j.1476-5381.1993.tb13773.x. [DOI] [PMC free article] [PubMed] [Google Scholar]